德視佳(01846.HK):上半年EBITDA增長23.6%達致1.42億港元 收益創下歷史新高
格隆匯8月29日丨德視佳(01846.HK)發佈公吿,截至2023年6月30日止六個月,收益創下3.464億港元的歷史新高,同比增長9.7%。股東應占溢利同比增加45.0%至6750萬港元,而淨利率增加5.9個百分點至19.7%。集團於本期間的EBITDA達致1.417億港元,增長23.6%,而EBITDA率增加至40.9%。董事會已議決宣派中期股息每股普通股0.0511港元。
該期間集團總收益同比上升9.7%,主要是由於用於治療老花眼的晶體置換手術在德國、中國及丹麥均錄得強勁增長;在與COVID-19疫情相關的限制取消後,集團在中國及丹麥進行的眼科手術數量大幅增加;及在德國採取有效的臨時定價策略,以恢復年輕一代患者羣體對屈光性激光手術的需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.